Press Releases

Co-Diagnostics, Inc. Announces Q1 2020 Results and Provides Mid-Second Quarter Update
Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter

Salt Lake City, Utah – May 14, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the filing of its operating results for the three-month period ending March 31, 2020, and provided updates on Company developments.

Q1 2020 Highlights:

  • Company commences COVID-19 test sales and reports $1.5 Million of revenue in Q1
  • Gross margins of 71.5% on sales of Logix Smart™ COVID-19 test kits
  • Raised capital with net proceeds of $18 million
  • First US company to receive CE marking for COVID-19 test kit (February 24)

Q2 2020 Mid-Quarter Highlights:

  • Receives FDA Emergency Use Authorization on COVID-19 test kit on April 3, 2020;
  • Company manufactures more than 6 million COVID-19 tests to date, and has ordered components for more than 20 million additional tests to fill existing and expected orders in the near future;
  • Records COVID-19 test and equipment sales of over $18 Million YTD through mid-second quarter (unaudited);
  • Receives COVID-19 test orders from public and private organizations in nearly 50 countries and over 15 states in the U.S.;
  • COVID-19 test kit shows 100% specificity and 100% sensitivity in several independent evaluations;

“Co-Diagnostics has increased production capacity to meet growing demand for our tests,” said Dwight Egan, Chief Executive Officer. “We have positioned the company to continue to make an important contribution in meeting the enormous demand for tests around the world. Our value proposition of accurate, high-throughput, and cost-effective tests continues to resonate with customers around the globe.”

The Company will host an earnings call at 4:30 pm EDT today. Analysts providing coverage for Co-Diagnostics will also be invited participate in a question and answer session. U.S. callers may dial toll free at 1-877-309-2073. International callers can access the call by dialing +1-646-749-3129. The access code to join the call is: 531-241-589. The call will be recorded and later made available on the Company’s website.

Forward-Looking Statements 

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.  Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.  

CO – DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

    March 31, 2020     December 31, 2019  
ASSETS:                
Current Assets                
Cash and cash equivalents   $ 17,369,323     $ 893,138  
Accounts receivables, net     1,055,738       131,382  
Inventory     686,078       197,168  
Prepaid expenses     499,327       362,566  
Total current assets     19,610,466       1,584,254  
Other Assets                
Property and equipment, net     276,454       186,832  
Investment in joint venture     593,421       434,240  
Total other assets     869,875       631,072  
                 
Total assets   $ 20,480,341     $ 2,215,326  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY:                
                 
Current Liabilities                
Accounts payable   $ 132,516     $ 5,959  
Accrued expenses     496,524       200,788  
Accrued expenses (related party)     120,000       120,000  
Deferred revenue     444,332       1,323  
Total current liabilities     1,193,372       328,070  
Long-term Liabilities, net of current portion                
Accrued expenses-long-term (related party)     120,000       150,000  
Total long-term liabilities, net of current portion     120,000       150,000  
Total liabilities     1,313,372       478,070  
                 
STOCKHOLDERS’ EQUITY                
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 and 25,600 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively           26  
                 
Common stock, $0.001 par value, 100,000,000 shares authorized; 27,451,064 and 17,342,922 shares issued and outstanding, as of March 31, 2020 and December 31, 2019, respectively.     27,451       17,343  
Additional paid-in capital     45,172,525       26,687,701  
Accumulated deficit     (26,033,007 )     (24,967,814 )
Total stockholders’ equity     19,166,969       1,737,256  
                 
Total liabilities and stockholders’ equity   $ 20,480,341     $ 2,215,326  

 

 

 

CO – DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

    For the Three Months
Ended March 31,
 
    2020     2019  
Net sales   $ 1,548,528     $ 3,400  
Cost of sales     481,740       452  
Gross profit     1,066,788       2,948  
Operating expenses:                
Sales and marketing     268,483       256,103  
Administrative and general     1,459,484       640,363  
Research and development     400,022       347,306  
Depreciation and amortization     20,748       13,668  
Total operating expenses     2,148,737       1,257,440  
Loss from operations     (1,081,949 )     (1,254,492 )
Other expense:                
Interest income     7,575       408  
Interest expense           (106,427 )
Gain on disposition of assets           850  
Gain (loss) on equity method investment in joint venture     9,181       (8,728 )
Total other expense     16,756       (113,897 )
Loss before income taxes     (1,065,193 )     (1,368,389 )
Provision for income taxes            
Net loss   $ (1,065,193 )   $ (1,368,389 )
                 
Basic and diluted income (loss) per common share   $ (0.05 )   $ (0.09 )
                 
Weighted average common shares outstanding, basic and diluted     22,820,450       16,066,633  

Company Contact:
Andrew Benson
Co-Diagnostics Investor Relations
801-438-1036
investors@codiagnostics.com
or
Investor Relations Contact:
Keith Pinder
Landon Capital
+1.404.995.6671
kpinder@landoncapital.net

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.

LATEST NEWS RELEASE

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.

Click here to learn more

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

COMPANY

 

© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.